<a href="${link:{uuid:{c90870f5-b8bd-4138-bee3-88766d4cee04},repository:{dam},path:{/Portal/UK/Prescribing-links/Clexane-pi.pdf}}}" target="_blank">Prescribing Information UK</a>

<h2>Dosing &amp; administration</h2>
Clexane®&nbsp;is an anticoagulant of the low-molecular-weight heparin (LMWH) class, derived from natural porcine heparin, to treat thrombosis.1

<h3>Dosage and administration guide</h3>

How to use the ERIS Clexane device

<h2>Device</h2>
Clexane is available in the syringe as seen below. There are several different doses of Clexane, so the syringes may look slightly different from the one shown here.

Automatic release of the safety mechanism when the plunger is fully depressed. Needle completely covered by the protection cap immediately after the injection.

<h2>Clear identification of different doses</h2>

<a href="/uk/thrombosis">SEE MORE FROM SCIENCE</a>

<h2>Get in touch with the Thrombosis Team</h2>

Clexane® (enoxaparin) Prescribing Information UK

THROMBOSIS

CARDIOLOGY

Clexane (enoxaparin) administration, device and doses

<h2> 
 About Pompe disease</h2>
Pompe disease is a rare, progressive, and potentially fatal neuromuscular disease that affects multiple organ systems in the body.3
Also known as acid alpha-glucosidase deficiency, acid maltase deficiency (AMD), and glycogen storage disease type II (GSD-II), Pompe disease is a type of lysosomal storage disease and is characterised by the progressive accumulation of glycogen in muscle cells.2,3

<h3>An estimated 1 in 40,000 people worldwide are living with Pompe disease&nbsp;4–6</h3>

<h2>What causes Pompe disease?</h2>
Pompe disease is a genetic disease, inherited in an autosomal recessive manner, and&nbsp; 
 is caused by dysfunctional or deficient acid alpha-glucosidase (GAA).2,3&nbsp;This is the&nbsp; 
 enzyme responsible for breaking down glycogen in the lysosomes of cells.2

When there is a GAA activity deficiency, glycogen accumulation progressively impairs skeletal, respiratory, and smooth muscle function.2,3
Glycogen accumulation can begin early in the Pompe disease process, before the onset of detectable symptoms, and lead to extensive and irreversible muscle damage.7
This early progression in Pompe disease pathology highlights the importance of early diagnosis and access to disease-specific care.1,5,7 
 &nbsp;

1.&nbsp;Pompe disease starts with a few glycogen-filled lysosomes, a stage where early muscle impairment may not be clinically detectable7

2.&nbsp;As glycogen accumulates, lysosomes expand and start to rupture causing progressive muscle weakness and functional impairment7

3.&nbsp;Increasing cytoplasmic glycogen damages the contractile structure of myofibrils, resulting in the development of more severe symptoms7

<h2>What are the different types of Pompe disease?</h2>
There are two main types of Pompe disease: 1:&nbsp;Late-onset Pompe disease (LOPD) and 2:&nbsp;Infantile-onset Pompe disease (IOPD) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;
<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">
 <h3>LOPD</h3></td>
 <td style="background-color: rgb(122, 210, 214);">
 <h3>IOPD</h3></td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">Symptoms can first present at any age3.&nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</td>
 <td style="background-color: rgb(122, 210, 214);">Onset is typically within the first few months of life 3,8</td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">Slowly progressive2,3</td>
 <td style="background-color: rgb(122, 210, 214);">Severe and rapid progression3</td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">GAA enzyme activity is usually between 1% and 40% of normal9&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</td>
 <td style="background-color: rgb(122, 210, 214);">GAA enzyme activity may be completely missing; if some remains, it is usually &lt;1% of normal9</td>
 </tr>
 </tbody>
</table>

LOPD and IOPD differ in terms of prevalence, age of onset, level of GAA enzyme activity, severity, and progression.2,3,4,9
Although there is a crossover of clinical symptoms that are observed in both LOPD and IOPD, there are some key differences.
Cardiac symptoms are often seen early in IOPD, but are rare in people with LOPD.2,8,10
L

To defy the average and reduce the delay in Pompe disease diagnosis start here.1
Learn about the genetic changes that cause the disease, and how these can be inherited within a family.2

POMPE

RARE-DISEASE

What is Pompe disease?

<h2>What is the burden of influenza for at-risk patients?</h2>

Some people may be at increased risk of influenza-related complications, including:1

Adults aged 65 + years

Those with underlying health conditions

Pregnant women

Babies and children

Flu vaccination is an essential part of helping protect communities29

<h2>What are the complications associated with the burden of Influenza?</h2>

<h3>Influenza may trigger other unwanted health complications for patients</h3>
Evidence indicates that influenza may trigger severe cardiovascular complications beyond respiratory infection.7
A self-controlled case series study conducted in Scotland showed that adults aged 40 years and older (median age 68), without a history of heart attack or stroke, were at a significantly increased risk of severe cardiovascular complications in the 1–3 days following a confirmed influenza infection.7

<h3>In the 1–3 days following a laboratory-confirmed influenza infection:a</h3>

Risk of having&nbsp;a heart attack7

Risk of having&nbsp;a stroke7

aIn a self-controlled case series study&nbsp;(based on a population in Scotland 2004-2014) conducted on a database of adults aged ≥ 40 years with ~90% of the study population aged 50 years and older. In the 1–3 days following a laboratory-confirmed influenza infection versus unexpected or baseline time periods.

CI, confidence interval; IR, incidence ratio.

<h2>Hospitalisations and economic burden of influenza</h2>
Influenza has an associated impact on healthcare costs and resources.
Influenza may have a considerable burden on secondary healthcare systems.30

Hospital admissions during the 2018/19 influenza season had associated medical costs of £99,565,310.1&nbsp;The highest costs were found to be associated with patients aged 65+ years.30

Certain groups may create increased pressure as they are more likely to experience a longer and more severe illness. During the 2018/19 influenza season:30

<table cellpadding="20" cellspacing="1" style="width:100%;">
 <tbody>
 <tr>
 <td style="background-color: rgb(122, 0, 230);">&lt;65 years</td>
 <td style="background-color: rgb(122, 0, 230);">
 75+ years</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Costs per hospitalisation:&nbsp;~£1,900</td>
 <td style="background-color: rgb(245, 247, 251);">
 Costs per hospitalisation: ~£3,700</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Average length of stay: 4.74 days</td>
 <td style="background-color: rgb(245, 247, 251);">
 Average length of stay: 12.55 days</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Mortality:&nbsp;1.83%</td>
 <td style="background-color: rgb(245, 247, 251);">
 Mortality:&nbsp;11.18%</td>
 </tr>
 </tbody>
</table>

Every year, millions of cases of influenza are recorded worldwide.

INFLUENZA

VACCINES

Burden of Influenza

At Sanofi, we have a rich history of MS research and treatment dating back to the 1970s. Through our partnership with Cambridge University, we have been at the forefront of delivering breakthrough medications to patients. Our commitment to patients and our passion for innovation in neurological disorders, such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and others, remains a top priority and investment for us.
We are driven by the desire to understand the science behind diseases like MS, which motivates us to challenge our assumptions and offer innovative solutions to meet the unmet needs of people affected by these conditions. With ongoing research into various treatments, we invite healthcare professionals to stay tuned for further updates and information later this year!

Thank you for visiting our Neurology page, and we look forward to your continued engagement and collaboration in advancing patient care.

MULTIPLE-SCLEROSIS

NEUROLOGY

Multiple Sclerosis

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>MAGE: patient satisfaction</h3>
MAGE was a real-world study investigating patient satisfaction in patients with T2D receiving&nbsp;Toujeo®.
There was an improvement of at least 2 points in DTSQ score at Month 6 from baseline, meeting the primary endpoint of the study.2
MAGE was a 6-month, multicentre, prospective, single-arm, observational, real-world study (conducted in Belgium) following 87 people with T2D who had been receiving basal and mealtime insulin for&nbsp;≥6 months.
Primary endpoint: change in DTSQ total score (baseline to Month 6).2
DTSQ: Diabetes Treatment Satisfaction Questionnaire.

Safety Profile

Abbreviations

References

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Lantus® (insulin glargine 100 units/mL) Prescribing Information GB

Lantus® (insulin glargine 100 units/mL) Prescribing Information NI

Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

TYPE-2-DIABETES

DIABETES

Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D

<h3>Treatment persistence3</h3>
Toujeo® (insulin glargine 300 Units/mL) was associated with better treatment persistence compared with insulin glargine 100 U/mL or insulin detemir in people with T2D.
The treatment persistence and hospitalisation retrospective analysis identified 181,263 people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3

Treatment persistence with basal insulin in adults with T2D

<h3>Hospitalisation3</h3>
Overall, a low number of episodes of hospitalised hypoglycaemia‡&nbsp;were observed in this study regardless of treatment.
The treatment persistence and hospitalisation retrospective analysis identified 181,263&nbsp;people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3&nbsp;
‡Hospitalisations for severe hypoglycaemia and associated diagnoses were identified with ICD 10 codes.3

Hospitalisation rates with basal insulin in adults with T2D

<h3>Addition of Toujeo® to GLP-1 RA was associated with significantly improved glycaemic control.9</h3>
DELIVER-G real-world retrospective analysis.
A real-world retrospective analysis in insulin-naïve adults with T2D inadequately controlled on GLP‑1 RA with or without oral antidiabetic drugs (N=271).9
DELIVER-G was a retrospective analysis of 271 people with Type 2 diabetes receiving GLP‑1 RA therapy who were insulin‑naive prior to subsequent treatment intensification with Toujeo® (insulin glargine 300 U/mL). DELIVER‑G analysed data from a large US electronic medical record data source (IBM® Explorys).9

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>Toujeo® versus degludec 100 U/mL in people with T1DM8</h3>
One Care study8
The first real-world study to compare 2nd-generation basal insulin analogues, Toujeo® and degludec 100 U/mL, in people with T1DM, using continuous glucose monitoring.8
The primary endpoint of the One Care study was effectiveness of Toujeo® versus insulin degludec 100 U/mL in terms of percentage of time in the predetermined glucose range (70-180 mg/dL). Time in range over the course of a full day was similar in both groups (52.4% for those receiving Toujeo® versus 49.3% for the insulin degludec group. At night the time in range was significantly higher in the Toujeo® group (52.4% versus 46.2%, p=0.0209).8
One Care was an observational, retrospective cohort, cross‑sectional, multicentre study of continuous glucose monitoring data in 199 adults with T1DM in Spain comparing the effectiveness (using percentage of time‑in‑range 70‑180 mg/dL over 14 consecutive days within a 4‑week period) and safety of Toujeo® (insulin glargine 300 units/mL) versus degludec using continuous glucose monitoring in routine clinical practice.8

Limitations of the One Care study:8
<ul>
 <li>No randomisation</li>
 <li>No centralised laboratory</li>
 <li>No intensive control and monitoring of clinical practice</li>
 <li>The degludec 100 U/mL group presented a more severe course of disease (higher rates of retinopathy) compared with the Toujeo® group</li>
</ul>

TYPE-1-DIABETES

Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles